Management of Hepatic Failure

Diagnostic Evaluation

• The American College of Physicians recommends performing blood analysis including serum acetaminophen levels, hepatitis A and hepatitis B serology, and toxicology screen in urine for substances like amphetamine and cocaine in patients with liver failure to guide specific treatments and predict outcomes 1, 2
• The American Association for the Study of Liver Diseases suggests conducting hepatic Doppler ultrasound to exclude chronic liver disease and verify vessel permeability in patients with liver failure 1, 3
• Echocardiography is recommended, especially when ischemic hepatocellular injury is suspected in patients with cardiac failure, arrhythmias, or when AST levels exceed ALT, to assess cardiac function and guide management 3
• Measurement of coagulation parameters, blood glucose, arterial blood gases, lactate levels, and arterial ammonia is crucial in patients with liver failure to assess the severity of the disease and guide management 4, 5

Organ System Management

Central Nervous System

• The Neurocritical Care Society recommends monitoring encephalopathy frequently and maintaining serum sodium levels between 140-145 mmol/L in patients with liver failure to prevent cerebral edema 1
• Blood glucose should be monitored at least every 2 hours in patients with liver failure to prevent hypoglycemia 1
• Tracheal intubation and sedation are recommended for progressive hepatic encephalopathy to protect the airway and prevent further brain injury 1
• Sedation depth should be minimized and benzodiazepines and psychotropic drugs like metoclopramide should be avoided in patients with liver failure to prevent worsening of encephalopathy 1

Cardiovascular System

• The American Heart Association recommends assessing volume status, cardiac output, and cardiac function in patients with liver failure to guide fluid and vasopressor management 1
• Crystalloid fluids are recommended as the first choice for fluid expansion in patients with liver failure to maintain cardiac output and prevent hypovolemia 1
• Norepinephrine is recommended for refractory hypotension in patients with liver failure to maintain blood pressure and perfusion of vital organs 1
• Pulmonary artery catheterization should be considered in hemodynamically unstable patients with liver failure to guide management and optimize cardiac function 6

Respiratory System

• The American Thoracic Society recommends implementing standard lung-protective ventilation strategies in patients with liver failure to prevent lung injury and improve outcomes 1

Renal System

• The National Kidney Foundation recommends providing renal replacement therapy according to specific recommendations in patients with liver failure to manage acute renal failure and prevent further complications 1
• Continuous rather than intermittent dialysis mode is recommended for acute renal failure in patients with liver failure to improve outcomes and reduce morbidity 6
• Nephrotoxic drugs, including NSAIDs, should be avoided in patients with liver failure to prevent further renal injury 1

Gastrointestinal System

• The American Gastroenterological Association recommends providing stress ulcer prophylaxis in patients with liver failure to prevent gastrointestinal bleeding and improve outcomes 1

Coagulation Management

• The American College of Chest Physicians recommends restricting clotting factor administration to cases with active bleeding only in patients with liver failure to prevent unnecessary transfusions and improve outcomes 1
• Coagulation abnormalities should not be routinely corrected unless active bleeding is present in patients with liver failure to prevent unnecessary interventions and improve outcomes 1

Infection Control

• The Infectious Diseases Society of America recommends administering empirical broad-spectrum antibiotics to patients with worsening hepatic encephalopathy or signs of SIRS to prevent infections and improve outcomes 1

Specific Treatments

• N-acetylcysteine should be administered systematically regardless of suspected etiology in patients with liver failure to improve outcomes and reduce morbidity 4
• Early contact with a transplant unit is recommended in patients with liver failure to consider liver transplantation and improve outcomes 4
• Etiology-specific treatments, such as acyclovir for Herpes simplex virus hepatitis, should be provided in patients with liver failure to improve outcomes and reduce morbidity 4
• Urgent liver transplantation should be considered when prognostic indicators suggest a high likelihood of death in patients with liver failure to improve survival and outcomes 6

Prognostic Considerations

• Poor prognostic indicators, such as idiosyncratic drug injury, non-hepatitis A viral infections, autoimmune hepatitis, mushroom poisoning, Wilson disease, Budd-Chiari syndrome, or indeterminate cause, may warrant consideration for transplantation in patients with liver failure to improve survival and outcomes 6
• Clinical indicators, such as higher grades of encephalopathy, may also warrant consideration for transplantation in patients with liver failure to improve survival and outcomes 6
• For acetaminophen-induced ALF, arterial pH <7.3 after adequate volume resuscitation, or PT >100 seconds with serum creatinine >3.4 mg/dL in patients with grade III/IV coma, may warrant consideration for transplantation to improve survival and outcomes 6
• For non-acetaminophen ALF, PT >100 seconds irrespective of coma grade, may warrant consideration for transplantation to improve survival and outcomes 6

Guideline Recommendations for Medication Management in Acute Liver Failure in the Emergency Department

Immediate Antidote Administration

• Initiate N‑acetylcysteine (NAC) as soon as acute liver failure (ALF) is recognized, regardless of etiology, because it reduces morbidity and mortality even in non‑acetaminophen cases. 7
• In suspected or confirmed acetaminophen toxicity, start NAC in the emergency department without awaiting serum acetaminophen levels.
  
  • Oral regimen: loading dose 140 mg/kg, then 70 mg/kg every 4 hours for 17 doses.
  • Intravenous regimen (preferred with altered mental status or gastrointestinal bleeding): 150 mg/kg over 15 min, then 50 mg/kg over 4 h, followed by 100 mg/kg over 16 h.
  • Give activated charcoal 1 g/kg immediately before NAC if presentation is ≤ 4 hours after ingestion. 8

Etiology‑Specific Antiviral and Antitoxin Therapies

• Begin acyclovir promptly for any patient with suspected or documented herpes simplex virus hepatitis causing ALF. 9
• For Amanita phalloides (mushroom) poisoning:
  
  • Administer Penicillin G 300 000–1 000 000 U/kg/day intravenously.
  • Give silymarin (silibinin) 30–40 mg/kg/day intravenously or orally for 3–4 days. [9][10]
• In hepatitis B‑related ALF, consider lamivudine (or adefovir) despite the lack of controlled‑trial evidence for acute disease. [9][10]

Medications to Avoid in ALF

• Benzodiazepines must be avoided because they worsen hepatic encephalopathy and increase mortality. [7][11]
• Metoclopramide and other psychotropic agents should be withheld. 7
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and any nephrotoxic drugs must be discontinued. 7
• Lactulose and rifaximin are not recommended, as they do not effectively lower ammonia in ALF. 7

Airway and Sedation Management

• Intubate patients whose Glasgow Coma Scale falls below 8 to protect the airway. 7

Infection Prevention and Empiric Therapy

• Start broad‑spectrum antibiotics immediately when encephalopathy worsens or systemic inflammatory response syndrome (SIRS) develops. 7
• Each hour of delay in the first antibiotic dose is associated with increased mortality; therefore, give the initial dose in the emergency department. 11
• Choose agents based on likely source: community‑acquired, healthcare‑associated, or nosocomial pathogens. 11
• Add antifungal coverage for intensive‑care patients with acute‑on‑chronic liver failure who fail to improve after 48 hours. 11

Gastro‑intestinal Protection

• Discontinue proton‑pump inhibitors when no clear indication exists to lower infection risk in chronic liver disease patients. 11

Coagulation Management

• Do not routinely correct coagulopathy with clotting factors unless there is active bleeding. 7
• Monitor INR and prothrombin time to track disease progression, not as predictors of bleeding risk. 11
• Restrict clotting‑factor administration to situations of active hemorrhage. 7
• Use viscoelastic testing (TEG/ROTEM) for functional assessment of coagulation, which is superior to INR alone. 11

Hemodynamic Support

• Use crystalloid solutions as first‑line volume expanders. 7
• Administer norepinephrine for refractory hypotension. 7

Metabolic Management

• Maintain serum sodium between 140–145 mmol/L to reduce the risk of cerebral edema. 7
• Check blood glucose at least every 2 hours. 7

Transplant Referral

• Contact a liver transplant center immediately upon diagnosis of ALF in the emergency department; delayed referral markedly worsens outcomes. 8